LVTX NL0015000AG6

Rapporto

Tempo differito Nasdaq - 20/05 21:36:06
3.440	USD		+2.38%

18/05	LAVA THERAPEUTICS N.V.: prospettiva positiva di SVB Securities LLC	MM
17/05	LAVA Therapeutics N.V. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2022	CI
12/05	Lava Therapeutics dice che la FDA ha approvato la domanda IND per Lava-051 per il trattamento della leucemia e di altre malattie; le azioni salgono.	MT

Notizie

Raccomandazione analisti

Altre lingue

Comunicati stampa

Pubblicazioni ufficiali

Notizie del settore

Notizie in altre lingue su LAVA THERAPEUTICS N.V.

17/05	LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2..
17/05	LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
17/05	LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
17/05	LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer
12/05	Lava Therapeutics Says FDA Clears IND Application for Lava-051 to Treat Leukemia, Other..
12/05	LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
12/05	LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
12/05	Lava Therapeutics N.V. Announces FDA IND Clearance for Lava-051 for the Treatment of He..
05/05	LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
05/05	LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
27/04	LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Societ..
27/04	LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Societ..
28/03	LAVA THERAPEUTICS N: Provides Business Update and Reports Fourth Quarter and Year End 202..
24/03	LAVA Therapeutics Q4 Net Loss Narrows as Revenue Declines
24/03	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021..
24/03	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021..
24/03	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 3..
24/03	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 20..
10/03	LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
10/03	LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
07/03	LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticanc..
07/03	LAVA Therapeutics N.V. Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Ant..
01/02	LAVA Therapeutics Doses First Patient in Clinical Trial of Potential Prostate Cancer Dr..
01/02	LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of ..
01/02	LAVA Therapeutics N.V. Announces Dosing of the First Patient in the Phase 1/2A Clinical..
28/01	Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthc..
28/01	Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthc..
18/01	LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Plat..
18/01	LAVA Therapeutics N.V. Presents Preclinical Data on its Gammabody™ T Cell Engager ..
2021	CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annu..
2021	CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annu..
2021	LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare C..
2021	LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
2021	Lava Therapeutics B.V. Reports Earnings Results for the Third Quarter and Nine Months E..
2021	LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Sy..
2021	LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Sy..
2021	LAVA Therapeutics Expands Management Team with Three Key Appointments
2021	LAVA Lava Therapeutics Appoints Sumeet Ambarkhane as Executive Medical Director
2021	LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Confere..
2021	LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
2021	Health Care Stocks Easing Slightly in Late Trade
2021	Health Care Stocks Advancing With Rising Friday Markets
2021	Health Care Stocks Climb Pre-Bell Friday
2021	LAVA Therapeutics Gets FDA Orphan Designation for LAVA-051
2021	LAVA THERAPEUTICS B: ' Leukemia Drug Candidate Gets FDA's Orphan Drug Designation; Shares..
2021	LAVA THERAPEUTICS B: Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment ..
2021	LAVA Therapeutics N.V. Receives FDA Orphan Drug Designation for LAVA-051 for the Treatm..
2021	Top Premarket Decliners
2021	LAVA Therapeutics Up 7% After Orphan Drug Designation
2021	CORRECTING AND REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell ..
2021	LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment o..
2021	Certain Common Shares of LAVA Therapeutics N.V. are subject to a Lock-Up Agreement Endi..
2021	Certain Share Options of LAVA Therapeutics N.V. are subject to a Lock-Up Agreement Endi..
2021	LAVA THERAPEUTICS B: N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (F..
2021	Lava Therapeutics B.V. Anticipates Data from the Phase 1 Dose Escalation Phase of the S..
2021	LAVA THERAPEUTICS B: Provides Business Update and Reports Second Quarter Results
2021	LAVA Therapeutics N.V. Announces Unaudited Consolidated Earnings Results for the Second..
2021	LAVA THERAPEUTICS B: Announces Appointment of Amy Garabedian as General Counsel and Corpo..
2021	LAVA Therapeutics N.V Announces Appointment of Amy Garabedian as Corporate Secretary
2021	LAVA THERAPEUTICS B: Doses First Patient in Study of Potential Cancer Drug
2021	LAVA THERAPEUTICS B: Announces Treatment of First Patient in Phase 1/2a Clinical Trial of..
2021	LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of ..
2021	LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
2021	LAVA THERAPEUTICS B: Unaudited Condensed Consolidated Interim Financial Statements as of ..
2021	LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
2021	LAVA Therapeutics N.V. Reports Earnings Results for the Three Months Ended March 31, 20..
2021	LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
2021	LAVA THERAPEUTICS B: Appoints Karen J. Wilson to its Board of Directors
2021	Lava Therapeutics B.V. Appoints Karen J. Wilson to its Board of Directors and as Chair ..
2021	LAVA THERAPEUTICS B.V.(NASDAQGS: LVTX) added to NASDAQ Composite Index
2021	LAVA Therapeutics N.V. has completed an IPO in the amount of $100.5 million.
2021	LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer
2021	LAVA Therapeutics N.V. has filed an IPO in the amount of $100 million.
2021	Lava Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors
2020	LAVA Therapeutics Announces $83 Million Series C Financing to Advance Novel Immuno-Onco..

1 2 Pross.

Prossimo evento su LAVA THERAPEUTICS N.V.

23/05/22

UBS Global Healthcare Conference

Calendario della società

Prossimi eventi del settore

26/07/22	IQVIA HOLDINGS INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
27/07/22	LONZA GROUP AG: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
28/07/22	SEAGEN INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
10/08/22	MODERNA, INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)

Più eventi

Settore

Sanità
	Biotecnologia/Farmaceutici
		Biotecnologia e ricerca medica
			Biotecnologia
				Biotecnologia e ricerca medica - Altri